Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Current Medicinal Chemistry. Anti-Cancer Agents|March 22, 2005
Anti-angiogenic therapy as a cancer treatment paradigmMohanraj Dhanabal, Mike Jeffers, William J Larochelle
Expert Opinion on Therapeutic Targets|September 12, 2002
Fibroblast growth factors in cancer: therapeutic possibilitiesMichael Jeffers, William J LaRochelle, Henri S Lichenstein
Biochemical and Biophysical Research Communications|June 14, 2005
Angioarrestin: a unique angiopoietin-related protein with anti-angiogenic propertiesMohanraj Dhanabal, Michael Jeffers, William J LaRochelle, et al.
Molecular Oncology|April 23, 2009
Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugateXiaozhong Qian, Evan Mills, Michael Torgov, et al.
Developmental Dynamics : an Official Publication of the American Association of Anatomists|October 31, 2007
FGFR2IIIb signaling regulates thymic epithelial differentiationJames Dooley, Matthew Erickson, William J Larochelle, et al.
International Journal of Cancer|November 22, 2007
Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancerXiaozhong Qian, Gulshan Ara, Evan Mills, et al.
International Journal of Radiation Biology|May 9, 2008
Velafermin (rhFGF-20) reduces the severity and duration of hamster cheek pouch mucositis induced by fractionated radiationGulshan Ara, Brynmor A Watkins, Haihong Zhong, et al.
Molecular Cancer Therapeutics|August 25, 2006
Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studiesXiaozhong Qian, William J LaRochelle, Gulshan Ara, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 20, 2007
PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritisPeter Boor, Andrzej Konieczny, Luigi Villa, et al.
Cancer Biology & Therapy|May 27, 2005
Recombinant semaphorin 6A-1 ectodomain inhibits in vivo growth factor and tumor cell line-induced angiogenesisMohanraj Dhanabal, Frank Wu, Enrique Alvarez, et al.
Pageof 2